CASSAVA SCIENCES INC·4

Nov 20, 4:39 PM ET

Landen Jaren 4

4 · CASSAVA SCIENCES INC · Filed Nov 20, 2024

Insider Transaction Report

Form 4
Period: 2024-11-18
Landen Jaren
Chief Clinical Dev. Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-11-18+85,00085,000 total
    Exercise: $27.95Exp: 2034-11-18Common Stock (85,000 underlying)
Footnotes (1)
  • [F1]The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on November 18, 2025.

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4